The popularity of Sildenafil initially drove a period of growth for pharma, nevertheless recent developments present a murky picture for those considering a stake. Off-patent versions are eroding earnings, and https://prestonitwg921223.therainblog.com/39724726/the-blue-pill-and-pharma-a-risky-bet